RTP Mobile Logo

Saturday, May 2, 2020, San Antonio, Texas, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA CNE (NCPD) Symposia Series Associated with the ONS 45th Annual Congress

Metastatic Lung Cancer

Update regarding COVID-19

The ONS Board of Directors has made the difficult decision to cancel the 45th Annual ONS Congress scheduled to take place in San Antonio, April 29-May 3, 2020. ONS is exploring alternatives for delivering the educational sessions. For up-to-date information on this program, please sign up for our email alerts.

Last updated 4/8/2020

Event Details

Location
Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)
Schedule
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
 
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Faculty
Faculty to be announced
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
 
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP and Merck during the Oncology Nursing Society’s (ONS) 45th Annual Congress, April 29 to May 3, 2020 in San Antonio, Texas. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

Agenda

Topics for Discussion

  • Module 1: Long-Term Management of EGFR-Positive Disease
  • Module 2: Current Treatment Algorithms for Patients with ALK- or ROS1-Positive Disease
  • Module 3: Management of RET-Positive Non-Small Cell Lung Cancer (NSCLC) and Other Potentially Targetable Mutations
  • MODULE 4: Clinical Approach to Metastatic NSCLC without a Targetable Mutation
  • MODULE 5: Small Cell Lung Cancer — Current and Future Management
A detailed agenda will be made available by late March.

CE Information

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Develop an understanding of the biologic basis for the investigation of immune checkpoint inhibitors for patients with advanced non-small cell (NSCLC) and small cell lung cancer (SCLC).
  • Evaluate recently published clinical trial data with the use of an anti-PD-1/PD-L1 antibody in combination with etoposide/platinum chemotherapy as first-line treatment of patients with extensive-stage SCLC, and identify individuals appropriate for treatment with this novel approach.
  • Recognize the incidence of genetic abnormalities commonly identified in patients with NSCLC, and counsel patients regarding how these may predict potential response (or lack thereof) to targeted therapy.
  • Review recent therapeutic advances related to the long-term management of metastatic NSCLC and an EGFR tumor mutation, and discern how this information should be applied to current patient care outside of a research setting.
  • Recall available clinical trial data documenting the safety and efficacy of approved ALK inhibitors in order to communicate to patients with ALK-rearranged metastatic NSCLC the rationale for individualized treatment recommendations.
  • Assess other oncogenic pathways (eg, ROS1, MET, RET, etc) mediating the growth of tumors in unique subsets, and recall published data with commercially available and experimental agents exploiting these targets.
  • Appreciate available clinical trial data with and the current role of anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy ± anti-angiogenic agents as first-line therapy for patients with metastatic NSCLC.
  • Consider existing guideline recommendations and expert perspectives regarding the selection and sequencing of available therapeutic options for patients with NSCLC who progress following first-line treatment with an immune checkpoint inhibitor.
  • Educate patients about the side effects associated with therapies commonly employed in the management of lung cancer, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NSCLC and SCLC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

Location

Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)

The Grand Hyatt San Antonio is conveniently located adjacent and connected to the Henry B Gonzalez Convention Center, where the ONS 45th Annual Congress is taking place.